Literature DB >> 26287645

Soluble ST2 and myocardial fibrosis in 3T cardiac magnetic resonance.

Silvio Quick1, Nadine K Waessnig1, Nadine Kandler1, David M Poitz1, Steffen Schoen2, Karim Ibrahim1, Ruth H Strasser1, Uwe Speiser1.   

Abstract

OBJECTIVE: The soluble form of ST2 (sST2) is a novel laboratory parameter for cardiac risk prediction, and over the past years, several studies have tried to evaluate its utility, especially in the management of heart failure. We investigated whether increased serum levels of sST2 show a characteristic pathomorphologic pattern in 3-Tesla cardiac magnetic resonance imaging (CMRI).
METHODS: One hundred and fifty-six patients referred to 3T CMRI due to suspected coronary artery disease (CAD) or myocarditis were prospectively enrolled in the study. Ninety patients were diagnosed with CAD, 22 patients with myocarditis, and 44 patients, who constituted the reference group, showed no pathologic CMRI pattern.
RESULTS: There was no significant difference between the sST2 values for patients in the reference group and patients with CAD or myocarditis. The sST2 concentration showed a weak correlation with the NYHA functional class (P = 0.002, r = 0.22), but correlation of sST2 and LGE, left ventricular parameters, and LVEF could not be seen. In contrast NT-proBNP was positively correlated to left ventricular parameters, LGE, and NYHA class function (P < 0.05). Additionally, it showed an inverse relationship to LVEF (P < 0.001, r = - 0.42).
CONCLUSIONS: Soluble ST2 is not able to detect myocardial scar and should not be used alone as a parameter for detection of inflammation and myocardial scar formation.

Entities:  

Keywords:  biomarker; cardiac magnetic resonance; fibrosis; heart failure; late gadolinium enhancement; sST2

Mesh:

Substances:

Year:  2015        PMID: 26287645     DOI: 10.3109/14017431.2015.1076936

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  5 in total

1.  Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study.

Authors:  Fuhai Li; Mengying Xu; Mingqiang Fu; Xiaotong Cui; Zhexun Lian; Hui Xin; Jingmin Zhou; Junbo Ge
Journal:  BMC Cardiovasc Disord       Date:  2021-08-17       Impact factor: 2.298

Review 2.  Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.

Authors:  Alexander E Berezin
Journal:  J Circ Biomark       Date:  2016-03-16

3.  Lack of Relationship between Fibrosis-Related Biomarkers and Cardiac Magnetic Resonance-Assessed Replacement and Interstitial Fibrosis in Dilated Cardiomyopathy.

Authors:  Paweł Rubiś; Ewa Dziewięcka; Magdalena Szymańska; Robert Banyś; Małgorzata Urbańczyk-Zawadzka; Maciej Krupiński; Małgorzata Mielnik; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska; Piotr Podolec; Mateusz Winiarczyk; Matylda Gliniak; Monika Kaciczak; Jan Robak; Arman Karapetyan; Ewa Wypasek
Journal:  Cells       Date:  2021-05-23       Impact factor: 6.600

4.  Correlation of serum ST2 levels with severity of diastolic dysfunction on echocardiography and findings on cardiac MRI in patients with heart failure with preserved ejection fraction.

Authors:  Vivek Agrawal; Suhas Hardas; Hasmukh Gujar; Deepak S Phalgune
Journal:  Indian Heart J       Date:  2022-03-09

5.  GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.

Authors:  Stefan Stojkovic; Alexandra Kaider; Lorenz Koller; Mira Brekalo; Johann Wojta; Andre Diedrich; Svitlana Demyanets; Thomas Pezawas
Journal:  J Cell Mol Med       Date:  2018-02-04       Impact factor: 5.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.